Key points from article :
Matt Kaeberlein argues that epigenetic reprogramming is genuinely exciting, but that the current evidence is still early. Animal studies suggest that partial reprogramming can restore function in damaged optic nerve and retinal cells, making the eye an important testing ground because these neurons normally do not regenerate well. However, he cautions that claims about “reversing ageing” or “curing blindness” go well beyond what has been shown so far.
The most likely near-term uses are specific retinal or optic nerve disorders, especially those linked to ageing or injury. The big unanswered questions are whether reprogramming can be done safely in humans and whether the benefits will be large enough to matter clinically. Because it changes fundamental gene-control systems, risks such as off-target effects, loss of cell identity and unknown long-term consequences need careful testing. Kaeberlein’s overall view is that the field is neither hype nor proven revolution: the promise is real, but the next decade of clinical evidence will decide how important it becomes.
